Patients receiving high-risk antineoplastic agents like doxorubicin require periodic echocardiographic monitoring due to the risk of decreased cardiac ejection function.
Which drugs are associated with risk signals and varying onset timings for decreased cardiac ejection function in the FAERS database?
Antineoplastic agents are strongly associated with decreased cardiac ejection function, necessitating tailored periodic echocardiographic monitoring based on the specific drug's onset timing.
This large-scale real-world analysis identifies both established and novel DCEF risk signals, highlights heterogeneity in onset timing, and emphasizes the predominance of antineoplastic agents. Clinically, these findings suggest the need for periodic echocardiographic monitoring of left ventricular ejection fraction, particularly in patients receiving high-risk drugs such as mitoxantrone, trastuzumab, doxorubicin, and pertuzumab. Early-phase monitoring is crucial for "early-failure" agents, while extended follow-up is warranted for drugs with delayed toxicity, such as doxorubicin. These results provide actionable evidence to support individualized risk management and regulatory label updates. .
Wang et al. (2026) studied this question. Patients receiving high-risk antineoplastic agents like doxorubicin require periodic echocardiographic monitoring due to the risk of decreased cardiac ejection function.